Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review

Chen, Jenny; Justicz, Natalie; Lee, Linda N.

doi:10.1055/s-0038-1660845

Cited by 35 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no complications reported other than transient edema/erythema and pain/headache associated with the procedure. PRP is considered a low-risk intervention to treat androgentic alopecia associated with good patient satisfaction and objective improvements in outcomes [6].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Alopecia Areata Barbae with Platelet-rich Plasma

Pototschnig

Madl²

2020

Cureus

View full text Add to dashboard Cite

Alopecia areata (AA) is a frequent autoimmune disorder in which inflammatory cells attack the hair follicles. AA affecting the beard area is well known and is referred to as alopecia areata barbae (AAB) when involvement is limited exclusively to the beard. Currently, no guidelines are established for specific therapeutic approaches for this condition. We present a case of a healthy 30-year-old male suffering from AAB. Three injections of platelet-rich plasma (PRP) with six-week intervals were applied. Stabilization of the condition was noted at the first follow-up (before the second injection), initial minimal hair regrowth was noted at the second follow-up (before the third injection) and robust regrowth at the one-year follow-up. To our knowledge, this case is the first report of a successful treatment of AAB using PRP. PRP represents a new, safe and potentially effective treatment option for AAB. More studies will be necessary to determine the efficacy of this treatment compared to conventional therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Alopecia Areata Barbae with Platelet-rich Plasma

Pototschnig

Madl²

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Platelet‐rich plasma treatment has been beneficial in the management of alopecia with reports of significantly increased hair density although lack of clinical improvements has also been reported in some patients. [ 6‐9,17 ] The source of this variability in clinical response could result from heterogeneity in amounts of GFs produced by platelets among patients undergoing PRP treatment. We evaluated GF secretion by activated platelets and provide evidence of variability in their amounts of TGFβ1, PDGF‐BB, EGF, VEGF and FGF2 secretion between patient samples.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneity in amount of growth factors secreted by platelets in platelet‐rich plasma samples from alopecia patients

Shaik

Estharabadi

Farah

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

Platelet α‐granules release growth factors (GFs) that promote healing and tissue regeneration. Platelet‐rich plasma (PRP) is shown to be beneficial in treating alopecia, and however, clinical response can be inconsistent. Due to several fold enrichment of platelets secreting large quantities of GFs following PRP injections, heterogeneity in amounts of GFs secreted by platelets may contribute to inconsistent clinical responses. Herein, we evaluated factors that could potentially contribute to heterogeneous secretion of GFs by platelets. We measured platelet secretion of transforming growth factor beta1 (TGFβ1), platelet‐derived growth factor (PDGF‐BB), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF2) in aliquots of de‐identified PRP samples from female patients undergoing therapy in the hair disease clinic. Although secretion of GFs by platelets was comparable in PRP samples of patients with non‐cicatricial and cicatricial alopecia, a Shapiro‐Wilk test for normal distribution indicated significant variability across all patient samples. The amount of GF secreted by platelets was comparable when PRP prepared from two FDA‐cleared devices with distinct techniques were compared. We provide evidence of platelets secreting heterogeneous amounts of GFs within each sample as high and low secretion of random factors could be simultaneously detected. These results suggest inherent heterogeneity in secretion of GFs by platelets in patient samples that are not influenced by the device used to prepare PRP. Since some GFs could have antagonistic effects on hair growth, a balance between amounts of growth promoting and inhibiting factors may be crucial in determining clinical response to PRP therapy.

show abstract

“…Thus, we included six additional RCTs not considered by Chen et al Chen et al did not mention that Gentile et al reported the identical data reported by Cervelli et al on 10 people, though this introduced duplicate data bias in favor of PRP. Chen et al concluded that PRP is a favorable low‐risk intervention for pattern hair loss. In concordance with the present review, the authors identified objective improvement of hair density and no serious complications.…”

Section: Discussionmentioning

confidence: 99%

“…One other RCT investigated PRP vs minoxidil, a comparison which did not match the inclusion criteria of the present review. Thus, we included six additional RCTs not considered by Chen et al 49 Chen et al 49 also suggested a good patient satisfaction. In RCTs, we did not find sufficient data on health-related quality of life, likely because we did not include cohort studies.…”

Section: Agreements and Disagreements With Other Studies Or Reviewsmentioning

confidence: 99%

Autologous platelet‐rich plasma therapy for pattern hair loss: A systematic review

Dervishi

Peternel

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Androgenetic alopecia (male pattern and female pattern hair loss) is characterized by thinning of the scalp hair. Intradermal injection of autologous platelet‐rich plasma (PRP) might have an effect on hair regrowth. Aims The aim was to evaluate efficacy and safety of platelet‐rich plasma compared to placebo or no treatment in people with pattern hair loss. Patients/Methods We searched the databases CENTRAL and MEDLINE on December 24, 2018 and included randomized controlled trials (RCTs). Primary outcomes were mean change of hair density from baseline and serious treatment‐related adverse events. Secondary outcome was mean change of hair thickness from baseline. Time point of outcome assessment was 6 months after start of treatment. Results We identified 13 relevant randomized controlled trials with 356 randomized (343 analyzed) people or half‐head areas who received PRP in a simple parallel or half‐head design. The pooled data of seven studies (171 analyzed people or half‐head areas) were favorable in the PRP group on hair density. We estimated a mean difference from baseline of 30.35 associated with a wide 95% confidence interval (1.77‐58.93), a considerable heterogeneity (I2 = 100%), and unclear risk of bias in most of the studies. Regarding hair thickness, data were also favorable in the PRP group, but these data were limited to a single study. We did not identify serious treatment‐related adverse events. Conclusion The results of seven RCTs indicated that autologous platelet‐rich plasma was associated with an increase of hair density when compared to placebo.

show abstract

Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review

Cited by 35 publications

References 39 publications

Successful Treatment of Alopecia Areata Barbae with Platelet-rich Plasma

Successful Treatment of Alopecia Areata Barbae with Platelet-rich Plasma

Heterogeneity in amount of growth factors secreted by platelets in platelet‐rich plasma samples from alopecia patients

Autologous platelet‐rich plasma therapy for pattern hair loss: A systematic review

Contact Info

Product

Resources

About